Epithelial Ovarian Cancer

P=N/A, N=35, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2027 --> Nov 2028 | Trial primary completion date: Oct 2026 --> Nov 2028

Perceived risk was intertwined with cancer worry, and individuals made decisions regarding RRSO based on factors such as perceived risk, control, family planning, hormonal impacts, and recovery. Importantly, healthcare providers exerted both direct and indirect influences on the decision-making process.

Finally, emerging combination strategies involving chemokine blockade together with immune checkpoint inhibitors, metabolic interventions, PARP inhibitors, and ferroptosis-related approaches are evaluated. However, successful clinical translation will require precise patient stratification, effective toxicity management, and validation in clinically annotated cohorts.

P3, N=404, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Initiation date: Apr 2026 --> Jul 2026

P1, N=19, Not yet recruiting, Shanghai Gynecologic Oncology Group

The critical role of mechanical signaling is demonstrated by both adipogenic conversion on soft substrates and the prevention of Ble-triggered adipogenesis following overexpression of a constitutive nuclear localization mutant of YAP. These findings establish that cytoskeletal destabilization in combination with adipogenic instructive cues enable the adipogenic reprogramming of EOC cells via heterochromatin remodeling, providing preclinical insights for ovarian cancer differentiation-targeted therapy.

Our study uncovers a previously unrecognized function of BRD4 in regulating histone lactylation and delineates the oncogenic BRD4/H4K12la/Ube2v1/DDX3X axis in EOC. These findings not only provide a profound mechanistic insight into EOC progression but also firmly establish the therapeutic rationale for targeting BRD4, via PROTAC inhibitors, in the treatment of EOC.

This case highlights a potential diagnostic pitfall in which benign extraovarian lesions may mimic metastatic disease, potentially leading to overstaging. It underscores the importance of integrating imaging findings with intraoperative evaluation and histopathological confirmation to ensure accurate staging and appropriate clinical management.

Although survival analyses did not demonstrate statistically significant independent prognostic associations, the findings support the biological relevance of CDK1 and TOP2A in EOC progression. Collectively, this study provides an integrated computational perspective on CDK1/TOP2A-associated oncogenic signaling and prioritizes Naringin as a preliminary candidate for future experimental investigation in epithelial ovarian cancer.

This review integrates current evidence on the molecular architecture and regulatory functions of BNC2, critically discusses its context-dependent roles across development and disease, and highlights unresolved questions regarding isoform-specific activity, cell-type-specific regulation, downstream target networks, and clinical translation. A clearer understanding of these mechanisms may support the future evaluation of BNC2 as a biomarker, genetic susceptibility locus, molecular stratification factor, and potential therapeutic regulatory node.

These findings provide preliminary evidence that IGF2 gene polymorphisms may be associated with the risk and clinicopathological characteristics of serous EOC in Chinese women.